Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00329992
Other study ID # 3200BO-102204
Secondary ID
Status Completed
Phase Phase 3
First received May 23, 2006
Last updated January 19, 2010
Start date April 2004
Est. completion date December 2009

Study information

Verified date January 2010
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

Participants are randomly assigned to either 16 sessions of Brief Eclectic Psychotherapy (Gersons et al. (2000) Journal Trauma Stress 13: 333-348), comprising psychoeducation, exposure, mementos and writing assignments, domain of meaning and integration, farewell ritual, or a minimal attention control group that will be offered 16 sessions of BEP after a waiting time of four months. Participants in the minimal attention control group receive monthly telephone calls and complete a symptom self monitoring diary (Tarrier, N. et al. (1999) Behavior Therapy 30: 597-605) for three weeks.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 2009
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Clear memory of an "index" traumatic event (sufficient for constructing a scene to be used in exposure) that occurred no less than six months prior to entering the trial (Montgomery and Bech 2000)

- PTSD according to the DSM-IV, related to the index traumatic event, as measured with the CAPS: frequency = 1 and intensity = 2 for a symptom to be counted plus a minimum level of overall severity = 50

- Not receiving other psychotherapy for PTSD during the 16 weeks of active treatment; psychotherapy for other problems, brief check-ins with an existing therapist, and attendance at self-help groups will be allowed

- If on psychoactive medication: on a stable medication regimen for a minimum of two months prior to entering the trial

- Aged between 18 and 70 years

- Sufficient proficiency in the German language to participate in BEP

- Consent to be randomized into the trial

Exclusion Criteria:

- Current psychotic, bipolar, substance-related, or severe personality disorder

- Current severe depressive disorder

- Severe cognitive impairment or a history of organic mental disorder

- Evidence of PTSD or depression immediately prior to the index trauma

- Ongoing threat of traumatic exposure

- Prominent current suicidal or homicidal ideation

- Asylum seeking status

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Brief Eclectic Psychotherapy for PTSD
16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD

Locations

Country Name City State
Switzerland Psychiatric Department, University Hospital Zurich

Sponsors (5)

Lead Sponsor Collaborator
University of Zurich Herrmann-Klaus-Stiftung, Switzerland, Jubiläumsspende für die Universität Zürich, Switzerland, Olga Mayenfisch Stiftung, Zurich, Switzerland, Swiss National Science Foundation

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary PTSD symptom severity (CAPS, Blake et al. 1998; Post-therapy / post-waitlist comparison, controlled for baseline scores Last month No
Secondary Ability to work and use of health care facilities Last months No
Secondary Comorbidity: Structured Clinical Interview for DSM-IV SCID I (First et al. 1996); Hospital Anxiety and Depression Scale HADS (Zigmond and Snaith 1983) Last month No
Secondary Questions on Life Satisfaction FLZ (Henrich and Herschbach 2000) Last month No
Secondary Posttraumatic Cognitions Inventory PTCI (Foa et al. 1999) Last month No
Secondary Posttraumatic Growth Inventory PGI (Tedeschi and Calhoun 1996) Since trauma No
Secondary EEG, event-related potentials: P300 At assessment No
Secondary Post-therapy / post-waitlist comparison, follow-up at 6month post therapy Last month No
See also
  Status Clinical Trial Phase
Completed NCT01188694 - Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD) Phase 2
Completed NCT01024140 - Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder N/A
Terminated NCT01574118 - Enhancing Exposure Therapy for Post-traumatic Stress Disorder Phase 2